Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
9
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
9
×
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
9
×
raleigh-durham blog main
9
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
pfizer
gene therapy
abbvie
cancer
deals
eli lilly
fda
immunotherapy
medicare
merck
What
roundup
bio
drug
patients
acquisitions
biggest
biotech
ceo
fda
moves
new
news
terms
won
according
advantages
akcea
albert
alzheimer’s
american
amgen
annual
approval
ash
august
bar
becker
billions
blood
borne
bourla
brings
build
busy
buy
cancers
candidates
cases
centers
cigarettes
Language
unset
unknown
Current search:
amgen
×
novartis
×
" detroit blog main "
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines